- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02049593 | PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 44 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT00981162 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | completed | Phase 1 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 |
| clinicaltrials |
| NCT01642342 | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | terminated | Phase 1 | 102 | University of Southern CaliforniaOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT01573780 | Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT01924260 | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer | completed | Phase 1 | 26 | Edward KimOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04428086 | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. | completed | Phase 1 | 19 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01497392 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | completed | Phase 1 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01527136 | Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 25 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01540253 | PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic | completed | Phase 1 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT05442996 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Jul 5, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | completed | Phase 1 | 53 | Cancer Research UKOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03600090 | Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer | completed | Phase 1 | 12 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03951116 | Study of FCN-437c in Patients With Advanced Solid Tumors(FCN-437c) | completed | Phase 1 | 22 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05242926 | Absorption and Excretion of Oral Docetaxel | withdrawn | Phase 1 | 0 | Modra PharmaceuticalsINDUSTRY | 1 | Feb 16, 2022 | clinicaltrials |
| NCT03673020 | Phase 1a Study to Evaluate Immunogenicity of ASV® | completed | Phase 1 | 3 | Agenus Inc.INDUSTRY | 1 | Dec 2, 2021 | clinicaltrials |
| NCT03147378 | Food Effect Study of ModraDoc006 in Combination With Ritonavir | completed | Phase 1 | 18 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT05084456 | Oral Docetaxel in Patients With Normal or Impaired Liver Function | withdrawn | Phase 1 | 0 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT05060263 | A Study of of HOT1030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Sep 29, 2021 | clinicaltrials |
| NCT04014257 | A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | completed | Phase 1 | 17 | Handok Inc.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04859777 | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | unknown | Phase 1 | 70 | Monopteros Therapeutics Inc.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02869295 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors(NKTR-214) | completed | Phase 1 / Phase 2 | 28 | Nektar TherapeuticsINDUSTRY | 1 | Jul 29, 2021 | clinicaltrials |
| NCT03360734 | Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors(GATTO) | completed | Phase 1 | 50 | Glycotope GmbHINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT04515043 | EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) | completed | Phase 1 | 6 | InvectysINDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT03706274 | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors | withdrawn | Phase 1 | 0 | CytomX TherapeuticsINDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT03992326 | Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors | terminated | Phase 1 | 6 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03318445 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | completed | Phase 1 | 22 | Pamela MunsterOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT01169532 | Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 16 | Fox Chase Cancer CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03976050 | Phase I Study of HL-085 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 4 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT01337765 | Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 29 | PfizerINDUSTRY | 5 | Oct 9, 2020 | clinicaltrials |
| NCT03008018 | Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours(HDAC6i) | completed | Phase 1 | 20 | Karus Therapeutics LimitedINDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT00002950 | Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 25 | Yale UniversityOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT03545815 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT00091299 | Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT00390156 | Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors | completed | Phase 1 | 35 | University of California, San FranciscoOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01470365 | 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors | completed | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT04169178 | Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status | unknown | Phase 1 | 98 | Henlix, IncINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT00003891 | Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 9, 2020 | clinicaltrials |
| NCT00003890 | MG98 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 19 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 6, 2020 | clinicaltrials |
| NCT00006036 | Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 14 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT00645060 | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 33 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01488513 | ABC294640 in Treating Patients With Advanced Solid Tumors(ABC-101) | completed | Phase 1 | 22 | RedHill Biopharma LimitedINDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT00036790 | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Sep 26, 2022source: clinicaltrials